Citigroup Inc. Has $14.95 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Citigroup Inc. decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 11.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 528,502 shares of the biopharmaceutical company's stock after selling 66,237 shares during the period. Citigroup Inc. owned approximately 0.09% of Royalty Pharma worth $14,951,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in RPRX. Swedbank AB increased its position in Royalty Pharma by 30.6% during the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company's stock worth $285,151,000 after buying an additional 2,533,570 shares during the period. Charles Schwab Investment Management Inc. increased its position in Royalty Pharma by 58.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company's stock worth $84,915,000 after buying an additional 1,103,341 shares during the period. New South Capital Management Inc. increased its position in shares of Royalty Pharma by 60.7% in the second quarter. New South Capital Management Inc. now owns 2,348,977 shares of the biopharmaceutical company's stock worth $61,943,000 after purchasing an additional 887,522 shares during the period. Dark Forest Capital Management LP increased its position in shares of Royalty Pharma by 2,974.4% in the second quarter. Dark Forest Capital Management LP now owns 338,675 shares of the biopharmaceutical company's stock worth $8,931,000 after purchasing an additional 327,659 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of Royalty Pharma by 69.0% in the second quarter. AQR Capital Management LLC now owns 785,567 shares of the biopharmaceutical company's stock worth $20,715,000 after purchasing an additional 320,606 shares during the period. Institutional investors own 54.35% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on RPRX shares. Citigroup decreased their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group raised their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a research report on Wednesday, August 14th. Finally, StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $41.67.

Royalty Pharma Price Performance

NASDAQ:RPRX traded up $0.31 during trading hours on Thursday, hitting $26.60. The company's stock had a trading volume of 1,811,546 shares, compared to its average volume of 2,645,659. The stock has a fifty day simple moving average of $27.16 and a 200-day simple moving average of $27.34. The company has a market capitalization of $15.67 billion, a P/E ratio of 13.78, a PEG ratio of 4.65 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. Royalty Pharma plc has a twelve month low of $25.10 and a twelve month high of $31.66.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.16%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma's dividend payout ratio (DPR) is presently 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.